RG
RARX

Redmile Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Redmile Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-110,769
Closed -$2.36M – 71
2017
Q1 		$2.36M Sell
110,769
-69,541
-39% -$1.33M 0.15% 55
2016
Q4 		$2.74M Buy
+180,310
New +$2.45M 0.24% 43

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group's RARX Position: Q2 2017 in Review

Redmile Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2017, closing a stake of 110,769 shares — an estimated $2.36M sold.

Redmile Group first reported a position in RARX in Q4 2016 and held it in 2 quarters. The position peaked at $2.74M in Q4 2016. 65 funds tracked by Wall St. Rank hold RARX as of Q2 2017.

  • Redmile Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Redmile Group sold 110,769 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2017, an estimated $2.36M.
  • Redmile Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Redmile Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.74M in Q4 2016.
  • 65 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Redmile Group's 13F filing for Q2 2017, filed 15 Aug 2017.